51B.F Bioventix PLC
- Market cap
- EUR 116M
- P/E
- 13.5x
- P/B
- 8.48x
- ROE
- 66.7%
- Dividend yield
- 7.95%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is 51B.F undervalued?
Graham number51B.F trades 125.2% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Bioventix PLC fundamental analysis
No fundamental analysis for Bioventix PLC yet.
Bioventix PLC stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Bioventix PLC
Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; Pyrene (HOP-G) ELISA kit, a sandwich enzyme-linked immunosorbent assay kit for the detection of 1-hydroxypyrene glucuronide in urine samples; and Pyrene (HOP-G) lateral kits, a positive read, semi-quantitat…
Full company profileBioventix PLC financial statements
Bioventix PLC annual financial statements (GBP; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 7.25M | 8.75M | 9.29M | 10.3M | 10.9M | 11.7M | 12.8M | 13.6M | 13.1M | 13.0M |
| Gross Profit | 6.75M | 8.18M | 8.41M | 9.49M | 10.1M | 11.0M | 12.0M | 12.7M | 11.9M | 11.9M |
| Operating Income | 5.71M | 6.90M | 7.03M | 7.98M | 8.38M | 9.18M | 10.1M | 10.6M | 10.1M | 10.0M |
| EBITDA | 5.81M | 6.93M | 7.03M | 8.11M | 8.52M | 9.42M | 10.2M | 10.7M | 10.2M | 10.3M |
| Net Income | 4.92M | 5.66M | 5.86M | 7.20M | 6.73M | 7.67M | 8.37M | 8.10M | 7.58M | 7.61M |
| EPS | 0.96 | 1.10 | 1.14 | 1.38 | 1.29 | 1.47 | 1.60 | 1.55 | 1.45 | 1.46 |
| Balance Sheet | ||||||||||
| Total Assets | 10.4M | 11.9M | 11.6M | 13.3M | 12.9M | 13.1M | 13.3M | 13.7M | 12.9M | 12.8M |
| Total Liabilities | 236K | 865K | 787K | 779K | 1.09M | 1.30M | 1.22M | 1.73M | 1.31M | 1.41M |
| Shareholders' Equity | 10.1M | 11.0M | 10.8M | 12.5M | 11.8M | 11.8M | 12.1M | 12.0M | 11.6M | 11.4M |
| Cash & Short-term Investments | 6.17M | 6.99M | 6.54M | 8.08M | 6.49M | 6.13M | 5.72M | 6.00M | 5.08M | 5.26M |
| Cash Flow | ||||||||||
| Operating Cash Flow | 3.96M | 5.92M | 5.88M | 7.68M | 6.34M | 7.56M | 7.80M | 8.34M | 7.03M | 7.95M |
| Capital Expenditure | 21.7K | 108K | 84.5K | 340K | 260K | 11.8K | 10.6K | 15.9K | 19.2K | 72.5K |
| Free Cash Flow | 3.87M | 5.81M | 5.79M | 7.34M | 6.08M | 7.55M | 7.79M | 8.33M | 7.01M | 7.88M |
| Ratios | ||||||||||
| ROE | 48.5% | 51.4% | 54.1% | 57.5% | 56.9% | 64.9% | 69.4% | 67.5% | 65.7% | 66.7% |
| ROA | 47.4% | 47.7% | 50.5% | 54.2% | 52.2% | 58.5% | 63.0% | 59.0% | 59.0% | 59.4% |
| Net Profit Margin | 67.9% | 64.7% | 63.1% | 69.8% | 61.6% | 65.5% | 65.3% | 59.5% | 57.8% | 58.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Bioventix PLC dividends
- Dividend yield
- 7.95%
- Forward dividend
- 1.76 EUR
- Payout ratio
- 102.9%
- Ex-dividend date
- Nov 5, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | GBP 7.84M | 1.50 | 102.9% |
| 2025 | GBP 8.19M | 1.57 | 108.0% |
| 2024 | GBP 8.25M | 1.58 | 101.9% |
| 2023 | GBP 8.44M | 1.62 | 100.8% |
| 2022 | GBP 7.92M | 1.52 | 103.2% |
| 2021 | GBP 7.71M | 1.48 | 114.5% |
| 2020 | GBP 6.50M | 1.25 | 90.3% |
| 2019 | GBP 3.27M | 0.64 | 55.8% |
| 2018 | GBP 2.76M | 0.54 | 48.8% |
| 2017 | GBP 3.37M | 0.66 | 68.5% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Bioventix PLC
- Insiders 7.71%
- Institutions 59.01%
- Public & others 33.29%
- Shares outstanding 5.22M
- Free float 4.15M
Bioventix PLC company profile
- Company name
- Bioventix PLC
- Ticker
- 51B.F
- ISIN
- GB00B4QVDF07
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 12
- Fiscal year end
- June
- Address
- 7 Romans Business Park, Farnham, United Kingdom, GU9 7SX
- Phone
- 44 12 5272 8001
- Website
- bioventix.com
About Bioventix PLC
Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; Pyrene (HOP-G) ELISA kit, a sandwich enzyme-linked immunosorbent assay kit for the detection of 1-hydroxypyrene glucuronide in urine samples; and Pyrene (HOP-G) lateral kits, a positive read, semi-quantitative lateral flow testing system that allows for monitoring of at-risk individuals. It also provides an industrial and environmental biomonitoring platform, as well as contract SMAs services. The company was incorporated in 2003 and is based in Farnham, United Kingdom.
Bioventix PLC management
2- Mr. Peter John Harrison MACEO & Director · born 1958
- Mr. Bruce Edward Heath HiscockCFO & Director · born 1958